{
    "2021-01-29": [
        [
            {
                "time": "",
                "orginal_text": "医药行业重大事项点评：国务院发布药品带量采购意见 应采尽采 范围更广",
                "features": {
                    "keywords": [
                        "药品带量采购",
                        "国务院",
                        "政策",
                        "范围更广"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "医药生物行业：药品集采常态化 坚定拥抱医药创新",
                "features": {
                    "keywords": [
                        "药品集采",
                        "常态化",
                        "医药创新"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "高瓴资本概念股普遍调整，凯莱英、健康元、金域医学、海正药业跌幅居前",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "概念股",
                        "调整",
                        "凯莱英",
                        "健康元",
                        "金域医学",
                        "海正药业"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "中泰证券--医药生物行业周报：CRO/CDMO行情将如何延续？长坡厚雪，未来可期【行业研究】",
                "features": {
                    "keywords": [
                        "CRO",
                        "CDMO",
                        "行情",
                        "长坡厚雪",
                        "未来可期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}